AKUMSPharmaceuticals
Akums Drugs & Pharmaceuticals Ltd — Cash Flow Statement
₹466.10
-3.81%
Akums Drugs & Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 192.88 Cr | 186.85 Cr | -152.16 Cr | -225.73 Cr | — |
| Repayment Of Debt | -123.86 Cr | -35.85 Cr | -10.76 Cr | -11.12 Cr | — |
| Issuance Of Debt | 0.00 | 10.29 Cr | 140.16 Cr | 20.02 Cr | — |
| Issuance Of Capital Stock | 637.37 Cr | 0.00 | — | — | — |
| Capital Expenditure | -272.31 Cr | -311.41 Cr | -328.79 Cr | -257.58 Cr | — |
| End Cash Position | 101.19 Cr | 111.05 Cr | 51.61 Cr | 55.14 Cr | — |
| Beginning Cash Position | 111.05 Cr | 51.61 Cr | 55.14 Cr | 22.07 Cr | — |
| Changes In Cash | -9.86 Cr | 59.82 Cr | -3.53 Cr | 33.07 Cr | — |
| Financing Cash Flow | 72.79 Cr | -108.02 Cr | 124.54 Cr | 236.04 Cr | — |
| Interest Paid Cff | -34.51 Cr | -50.41 Cr | -40.44 Cr | -8.91 Cr | — |
| Net Common Stock Issuance | 637.37 Cr | 0.00 | — | — | — |
| Common Stock Issuance | 637.37 Cr | 0.00 | — | — | — |
| Net Issuance Payments Of Debt | -477.90 Cr | -49.19 Cr | 177.98 Cr | 261.32 Cr | — |
| Net Short Term Debt Issuance | -354.04 Cr | -23.63 Cr | 48.58 Cr | 252.42 Cr | — |
| Net Long Term Debt Issuance | -123.86 Cr | -25.56 Cr | 129.40 Cr | 8.90 Cr | — |
| Long Term Debt Payments | -123.86 Cr | -35.85 Cr | -10.76 Cr | -11.12 Cr | — |
| Long Term Debt Issuance | 0.00 | 10.29 Cr | 140.16 Cr | 20.02 Cr | — |
| Investing Cash Flow | -547.84 Cr | -330.42 Cr | -304.70 Cr | -234.82 Cr | — |
| Interest Received Cfi | 24.99 Cr | 12.00 Cr | 7.88 Cr | 4.63 Cr | — |
| Net Investment Purchase And Sale | -309.06 Cr | -63.48 Cr | -44.99 Cr | 24.36 Cr | — |
| Purchase Of Investment | -309.06 Cr | -63.48 Cr | -44.99 Cr | — | — |
| Net PPE Purchase And Sale | -263.76 Cr | -286.42 Cr | -286.65 Cr | -255.66 Cr | — |
| Sale Of PPE | 8.55 Cr | 24.99 Cr | 42.15 Cr | 1.92 Cr | — |
| Purchase Of PPE | -272.31 Cr | -311.41 Cr | -328.79 Cr | -257.58 Cr | — |
| Operating Cash Flow | 465.20 Cr | 498.26 Cr | 176.63 Cr | 31.85 Cr | — |
| Taxes Refund Paid | -81.23 Cr | -62.42 Cr | -97.06 Cr | -54.82 Cr | — |
| Change In Working Capital | 33.47 Cr | 49.87 Cr | -34.33 Cr | -351.56 Cr | — |
| Change In Other Current Liabilities | -24.11 Cr | 21.53 Cr | -34.65 Cr | 113.54 Cr | — |
| Change In Other Current Assets | -49.30 Cr | -33.37 Cr | -18.31 Cr | -56.87 Cr | — |
| Change In Payable | 119.23 Cr | -29.20 Cr | -18.37 Cr | 250.51 Cr | — |
| Change In Inventory | -50.57 Cr | 83.73 Cr | -7.35 Cr | -292.59 Cr | — |
| Change In Receivables | 34.10 Cr | -3.23 Cr | 34.91 Cr | -371.77 Cr | — |
| Other Non Cash Items | 3.22 Cr | 33.06 Cr | 14.45 Cr | 8.87 Cr | — |
| Provisionand Write Offof Assets | 20.32 Cr | 36.70 Cr | 1.86 Cr | 12.09 Cr | — |
| Deferred Tax | -1.93 Cr | 0.00 | — | — | — |
| Depreciation And Amortization | 153.45 Cr | 125.64 Cr | 112.81 Cr | 94.68 Cr | — |
| Amortization Cash Flow | 2.65 Cr | 2.21 Cr | 1.85 Cr | 2.99 Cr | — |
| Depreciation | 150.80 Cr | 123.44 Cr | 110.96 Cr | 91.69 Cr | — |
| Gain Loss On Investment Securities | -3.87 Cr | 357.77 Cr | -43.97 Cr | 494.17 Cr | — |
| Gain Loss On Sale Of PPE | -3.71 Cr | 0.18 Cr | -4.58 Cr | 2.07 Cr | — |
| Net Income From Continuing Operations | 345.25 Cr | -45.28 Cr | 150.30 Cr | -193.20 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | -0.38 Cr | — | — | 0.51 Cr |
| Net Other Investing Changes | — | 0.10 Cr | 22.51 Cr | — | — |
| Sale Of Investment | — | 0.00 | 0.00 | 24.36 Cr | — |
| Net Business Purchase And Sale | — | 0.00 | -1.58 Cr | -10.65 Cr | -59.98 Cr |
| Sale Of Business | — | 0.00 | 0.04 Cr | 0.35 Cr | 0.52 Cr |
| Purchase Of Business | — | 0.00 | -1.62 Cr | -11.00 Cr | -60.50 Cr |
| Gain Loss On Sale Of Business | — | — | 0.20 Cr | -0.20 Cr | -0.35 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Akums Drugs & Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.